Compugen to Present at Two Oncology Conferences in March
March 02 2015 - 6:09AM
Business Wire
Presentations include experimental data
demonstrating potential of Compugen-discovered novel immune
checkpoints as targets for cancer immunotherapy
Compugen Ltd. (NASDAQ: CGEN) today announced that it will
present aspects of its immune checkpoint related research at two
oncology conferences this month.
Galit Rotman, PhD, Chief Scientist of Therapeutics at Compugen,
will deliver an oral presentation at the Immune Checkpoint
Inhibitors conference to be held from March 24-26 in Boston. Dr.
Rotman’s talk titled Novel Immune Checkpoints as Antibody Targets
for Cancer Immunotherapy is part of a session named Validate Novel
Pathways For Blockade Therapy. In her talk, Dr. Rotman will present
experimental data demonstrating the immunomodulatory function of
selected Compugen-discovered novel immune checkpoints as target
candidates for cancer immunotherapy.
In addition, Dr. Rotman will participate in a panel discussion
on immuno-oncology at the Phacilitate Oncology Leaders’ Forum on
March 24, also taking place in Boston.
About Compugen’s Programs for Cancer Immunotherapy
Compugen’s cancer immunotherapy programs are based on eleven
novel predicted B7/CD28-like immune checkpoint candidates and four
novel immunomodulators distinct from the B7/CD28-like proteins, all
of which were initially predicted in silico by Compugen.
Immune checkpoints, including inhibitory receptors and ligands, are
immunomodulatory proteins which are crucial for the maintenance of
self-tolerance (the prevention of autoimmunity) and for the
protection of tissues from damage during an immune response. Immune
checkpoints are "hijacked" by tumors to block the ability of the
immune system to destroy the tumor cells. Therapeutic blockade of
immune checkpoints can boost anti-tumor immunity, enabling the
patient’s immune system to recognize and attack the tumor cells,
and mount durable anti-tumor responses leading to tumor
destruction.
About Compugen
Compugen is a leading drug discovery company focused on
monoclonal antibodies and therapeutic proteins to address important
unmet needs in the fields of oncology and immunology. The
Company utilizes a broad and continuously growing integrated
infrastructure of proprietary scientific understandings and
predictive platforms, algorithms, machine learning systems and
other computational biology capabilities for the in
silico (by computer) prediction and selection of novel drug
target candidates, which are then advanced in its Pipeline Program.
The discovery and development of monoclonal antibody therapeutic
candidates against selected Compugen-discovered novel target
candidates is performed by Compugen’s wholly-owned U.S. subsidiary
located in South San Francisco. The Company's business model
includes collaborations covering the further development and
commercialization of product candidates at various stages from its
Pipeline Program and various forms of research and discovery
agreements, in both cases providing Compugen with potential
milestone payments and royalties on product sales or other forms of
revenue sharing. For additional information, please visit
Compugen's corporate website at www.cgen.com.
Forward Looking Statement
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
terminology such as “will,” “may,” “expects,” “anticipates,”
“believes,” and “intends,” and describe opinions about future
events and include statements related to the potential of
Compugen-discovered novel immune checkpoints as targets for cancer
immunotherapy. These forward-looking statements involve known and
unknown risks and uncertainties that may cause the actual results,
performance or achievements of Compugen to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. Some of these and other
factors are discussed in the "Risk Factors" section of Compugen’s
most recent Annual Report on Form 20-F as filed with the Securities
and Exchange Commission as well as other documents that may be
subsequently filed by Compugen from time to time with the
Securities and Exchange Commission. In addition, any
forward-looking statements represent Compugen’s views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements
unless required by law.
Compugen Ltd.Tsipi Haitovsky, +972-52-598-9892Global Media
Liaisontsipih@cgen.com
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024